Adenovirus infection and disease in relation to T-cell depletion.

The solid line represents patients receiving alemtuzumab in vivo (50/100 mg). (A) Adenovirus infection: events in 12 of 31, probability 45%; 95% CI, 28-62.9. (B) Disease: events in 6 of 31, probability 27%; 95% CI, 8-46. The broken line represents patients receiving alemtuzumab in vitro (10 mg/20 mg). (A) Adenovirus infection: events in 3 of 31, probability 11%; 95% CI, 1-21.9. (B) Disease: events in 0 of 31. The dotted line represents patients not receiving alemtuzumab antibodies (A and B: events in 0 of 14). The difference was significant with log rank: P = .001 for adenovirus infection (A) and P = .005 for adenovirus disease (B). The Δ indicate censured patients in alemtuzumab in vitro group; ○, censured patients in no alemtuzumab group.